Lexeo Therapeutics (NASDAQ:LXEO) Given New $25.00 Price Target at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective boosted by Chardan Capital from $23.00 to $25.00 in a report issued on Wednesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Lexeo Therapeutics in a research report on Thursday, October 31st. Finally, Leerink Partners reduced their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $22.71.

Lexeo Therapeutics Trading Down 0.7 %

NASDAQ:LXEO opened at $7.64 on Wednesday. The company has a current ratio of 9.38, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 1-year low of $7.47 and a 1-year high of $22.33. The firm has a market capitalization of $252.58 million and a price-to-earnings ratio of -0.52. The business’s 50-day moving average price is $9.16 and its two-hundred day moving average price is $12.30.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, meeting analysts’ consensus estimates of ($0.64). On average, equities analysts expect that Lexeo Therapeutics will post -2.76 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $977,629.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 12,500 shares of company stock valued at $113,300. Company insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth about $75,000. Vanguard Group Inc. boosted its position in Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after purchasing an additional 65,573 shares during the period. American International Group Inc. bought a new stake in shares of Lexeo Therapeutics during the 1st quarter worth about $79,000. Janus Henderson Group PLC raised its holdings in Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after acquiring an additional 210,047 shares during the period. Finally, Artal Group S.A. lifted its position in Lexeo Therapeutics by 32.9% during the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after acquiring an additional 198,281 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.